Day: November 21, 2019

TEL AVIV, Israel, Nov. 21, 2019 (GLOBE NEWSWIRE) — VBL Therapeutics (Nasdaq: VBLT) today announced that data on the new investigator-sponsored Phase 2 study of VB-111 in recurrent glioblastoma (rGBM) will be presented by Timothy Cloughesy, M.D., Director and Professor, UCLA Neuro-Oncology Program at the 2019 Society for Neuro-Oncology (SNO) annual meeting, being held November 20-24, 2019 in Phoenix, Arizona.The randomized, controlled clinical trial will study VB-111 in rGBM patients undergoing a second surgery. VB-111 will be administrated either before (‘neo-adjuvant’) and after the surgery (‘adjuvant’), or just after the surgery, and will be compared to a third cohort that will receive standard of care as control.  The trial will be conducted at seven top neuro-oncology US centers: Dana-Farber Cancer Institute,...

NEW YORK and LONDON, Nov. 21, 2019 (GLOBE NEWSWIRE) — MarketAxess Holdings Inc. (Nasdaq: MKTX), the operator of a leading electronic trading platform for fixed-income securities, and the provider of market data and post-trade services for the global fixed-income markets, announced today that Bank Julius Baer & Co. Ltd (Julius Baer), one of the world’s leading private banking groups, has gone live with a pilot version of MarketAxess’ new order and execution workflow solution, Axess IQ.Axess IQ is designed to meet the needs of wealth management and private banking community by improving liquidity discovery, execution efficiency and alpha generation across execution operations of firms with large numbers of individual client orders. The connectivity of Axess IQ and the MarketAxess trading network means clients can access unparalleled...

VANCOUVER, British Columbia, Nov. 21, 2019 (GLOBE NEWSWIRE) — Kutcho Copper Corp. (TSXV: KC) (OTC: KCCFF) (“Kutcho Copper” or the “Company”) is pleased to announce results of ongoing metallurgical testing on its 100% owned Kutcho Project in British Columbia, Canada. These latest results show improved copper, zinc and silver recoveries, higher concentrate grades and improved separation of copper and zinc into their respective concentrates. This test program is part of the work completed or underway that is designed to support completion of a Feasibility Study for the Kutcho Project.Leading up to recent Locked Cycle Tests extensive mineralogical evaluations carried out on drill core composites by QEMSCAN have been completed and incorporated into block models to fully quantify and characterize the mineralization in terms of mineral...

– Former Chairman, CEO, and senior executive at numerous biotechnology and pharmaceutical companies brings strong clinical and commercial experience to support advancement of the Company’s ImmTOR™ platform –WATERTOWN, Mass., Nov. 21, 2019 (GLOBE NEWSWIRE) — Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform technology, ImmTOR™, today announced the appointment of Carrie S. Cox to the position of Chairman of the Board of Directors, effective immediately.“Ms. Cox has a demonstrated track record of success working with both biotechnology and large pharmaceutical companies. Her addition to our Board of Directors is extraordinarily valuable, as we advance the ImmTOR platform for our lead program, SEL-212,...

Proprietary cap ensures the freshest possible drink and extended shelf lifePHOENIX, AZ, Nov. 21, 2019 (GLOBE NEWSWIRE) — via NEWMEDIAWIRE — Today American Green (ERBB:OTC) is pleased to announce that it has signed an agreement with Vessl Inc. of Tempe, AZ, which owns a patented bottle closure, that provides instant and pressurized mixing of ingredients stored in the bottle cap which is released immediately prior to consumption. American Green plans to use the technology to deliver pharmaceutical CBD to consumers just prior to the drink’s consumption while extending the product’s shelf life of the bottle’s contents prior to sale or use. Click here for a video on how the process works.American Green will have distribution for its new, patented CBD Drinks online at americangreencbd.com, in stores, and in the company’s proprietary...

HOUSTON, Nov. 21, 2019 (GLOBE NEWSWIRE) — Bio-Path Holdings, Inc., (NASDAQ:BPTH), a biotechnology company leveraging its proprietary DNAbilize® antisense RNAi nanoparticle technology to develop a portfolio of targeted nucleic acid cancer drugs, today announced that the U.S. Food and Drug Administration (FDA) has reviewed and cleared the Investigational New Drug (IND) application for BP1002 (liposomal Bcl-2), the Company’s second drug candidate. An initial Phase 1 clinical trial will evaluate the ability of BP1002 to treat refractory/relapsed lymphoma and chronic lymphocytic leukemia patients. BP1002 targets the protein Bcl-2, which is responsible for driving cell survival in up to 60% of all cancers. High expression of Bcl-2 has been correlated with adverse prognosis for patients diagnosed with relapsed, aggressive non-Hodgkin’s...

Baltic Horizon Fund kutsub osakuomanikke, investoreid, analüütikuid ja teisi huvilisi osalema oma investorite veebiseminaril 27. novembril 2019.a. kell 13:00 (CET) / 14:00 (EET).Veebiseminari juhib Baltic Horizon Fund fondijuht Tarmo Karotam. Presentatsioonile järgneb küsimustevoor. Piiratud aja tõttu soovitame osalejatel saata oma küsimused hiljemalt üks päev varem, enne veebiseminari toimumist e-mailile tarmo.karotam@nh-cap.com.Veebiseminaril osalemiseks palume teil registreerida järgneva lingi kaudu: https://attendee.gotowebinar.com/register/5258136586402942477Teile saadetakse link ning juhised veebiseminariga liitumiseks. Kui osalete veebiseminaril esimest korda, palutakse teil alla laadida vajalik rakendus, mis võtab vaid mõned sekundid. Juhul kui rakenduse allalaadimine ei õnnestu, avaneb automaatselt veebibrauser, mille kaudu on...

Baltic Horizon Fund invites unitholders, investors, analysts and other stakeholders to join its investor conference webinar, scheduled on 27 November 2019 at 13:00 PM (CET) or 14:00 PM (EET).The webinar will be hosted by Tarmo Karotam, the Fund Manager of Baltic Horizon Fund. Q&A session will follow after the presentation. Due to limited webinar time, we encourage participants to send their questions no later than one day before the webinar to tarmo.karotam@nh-cap.com.To join the webinar, please register via the following link: https://attendee.gotowebinar.com/register/5258136586402942477You will be provided with the webinar link and instructions how to join successfully. When joining the webinar for the first time, you will be asked to download the plug-in which will take only few seconds. In case plug-in can’t be downloaded,...

Westport, CT, Nov. 21, 2019 (GLOBE NEWSWIRE) — BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the “Company”), a medical technology company developing a proprietary biomedical signal processing platform designed to improve signal fidelity and uncover the full range of ECG and intra-cardiac signals, today announced that the Company commenced its first clinical trial for its PURE EP™ System.Texas Cardiac Arrhythmia Research Foundation (TCARF) in Austin, Texas, is the first institution to conduct patient cases under the clinical trial titled, “Novel Cardiac Signal Processing System for Electrophysiology Procedures (PURE EP 2.0 Study)”. Eight patient enrollments were achieved during the first week of the trial. The data collected during the trial is planned to be submitted for abstract consideration at leading industry events...

Niðurstaða hluthafafundar Símans hf. sem haldinn var fimmtudaginn 21. nóvember 2019 kl. 10. í höfuðstöðvum félagsins.Tillaga um að afturkalla umboð stjórnarmanna, sbr. 1. mgr. 64. gr. laga nr. 2/1995 um hlutafélög.Tillagan var samþykkt.Stjórnarkjör skv. grein 15.1 í samþykktum félagsins.Eftirtaldir aðilar voru kjörnir í stjórn félagsins:Bjarni ÞorvarðarsonHelga ValfellsJón SigurðssonKolbeinn ÁrnasonSylvía Kristín ÓlafsdóttirÞeir fimm aðilar sem flest atkvæði fengu teljast réttkjörnir til stjórnarsetu í Símanum hf. til næsta aðalfundar.Staðfesting á ákvörðun aðalfundar dags. 21. mars 2019 varðandi stjórnarkjör og breytingar á viðauka við samþykktir. Ákvarðanir aðalfundar 21. mars 2019 voru staðfestar.Ekki voru fleiri mál á dagskrá fundarins.